2021 ICD-10-CM Code C92.Z1

Other myeloid leukemia, in remission

Version 2021

Valid for Submission

C92.Z1 is a billable diagnosis code used to specify a medical diagnosis of other myeloid leukemia, in remission. The code C92.Z1 is valid during the fiscal year 2021 from October 01, 2020 through September 30, 2021 for the submission of HIPAA-covered transactions.

The ICD-10-CM code C92.Z1 might also be used to specify conditions or terms like acute myeloid leukemia in remission, acute myeloid leukemia with maturation, fab m2, acute myeloid leukemia with maturation, fab m2, in remission, acute myeloid leukemia without maturation, fab m1, acute myeloid leukemia without maturation, fab m1 in remission , acute myeloid leukemia, minimal differentiation, fab m0, etc.

ICD-10:C92.Z1
Short Description:Other myeloid leukemia, in remission
Long Description:Other myeloid leukemia, in remission

Code Classification

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

Convert C92.Z1 to ICD-9 Code

The General Equivalency Mapping (GEM) crosswalk indicates an approximate mapping between the ICD-10 code C92.Z1 its ICD-9 equivalent. The approximate mapping means there is not an exact match between the ICD-10 code and the ICD-9 code and the mapped code is not a precise representation of the original code.

Information for Patients


Acute Myeloid Leukemia

Also called: AML, ANLL, Acute myelogenous leukemia

Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute myeloid leukemia (AML), there are too many of a specific type of white blood cell called a myeloblast.

AML is the most common type of acute leukemia in adults. This type of cancer usually gets worse quickly if it is not treated. Possible risk factors include smoking, previous chemotherapy treatment, and exposure to radiation.

Symptoms of AML include:

Tests that examine the blood and bone marrow diagnose AML. Treatments include chemotherapy, other drugs, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back.

NIH: National Cancer Institute


[Learn More in MedlinePlus]

Chronic Myeloid Leukemia

Also called: CML, Chronic granulocytic leukemia, Chronic myelogenous leukemia

Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In chronic myeloid leukemia (CML), there are too many granulocytes, a type of white blood cell.

Most people with CML have a gene mutation (change) called the Philadelphia chromosome.

Sometimes CML does not cause any symptoms. If you have symptoms, they may include:

Tests that examine the blood and bone marrow diagnose CML. Treatments include chemotherapy, stem cell transplants, infusion of donated white blood cells following stem cell transplants, surgery to remove the spleen, and biologic and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells.

NIH: National Cancer Institute


[Learn More in MedlinePlus]

Code History

  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016 (First year ICD-10-CM implemented into the HIPAA code set)